OpGen, Inc. (OPGN)
After hours:
- GlobeNewswire
OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients
Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of pathogens by Unyvero HPNAdditional pathogens detected by Unyvero HPN confirmed in many instances by culture positivity for the same microorganism in another sample obtained from the same patientThis observation highlights the ability of Unyvero HPN in detecting potential pneumonia pathogens earlier than culture ROCKVILLE, Md., June 22, 2022 (GLOBE N
- GlobeNewswire
OpGen Announces 1,000th Patient Sample Enrolled in Clinical Trial for Unyvero Urinary Tract Infection Panel
Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sampleFourth trial site added to optimize enrollment for different sample types and accelerate trial completionClinical performance evaluation aims at a subsequent FDA submission ROCKVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious
- GlobeNewswire
OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar
Exclusive distribution agreement for initial term of three yearsLeader Life Sciences commits to minimum purchase of 8 Unyvero systems during initial term Leader Life Sciences to seek regulatory clearance for Unyvero products in U.A.E. and Qatar ROCKVILLE, Md., June 09, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that its subsidiary Cur
